全文获取类型
收费全文 | 1302929篇 |
免费 | 101797篇 |
国内免费 | 2068篇 |
专业分类
耳鼻咽喉 | 18803篇 |
儿科学 | 45427篇 |
妇产科学 | 35900篇 |
基础医学 | 185313篇 |
口腔科学 | 34661篇 |
临床医学 | 113948篇 |
内科学 | 262780篇 |
皮肤病学 | 28704篇 |
神经病学 | 102968篇 |
特种医学 | 52374篇 |
外国民族医学 | 660篇 |
外科学 | 199912篇 |
综合类 | 27208篇 |
现状与发展 | 1篇 |
一般理论 | 395篇 |
预防医学 | 97928篇 |
眼科学 | 28377篇 |
药学 | 96978篇 |
2篇 | |
中国医学 | 2427篇 |
肿瘤学 | 72028篇 |
出版年
2019年 | 9804篇 |
2018年 | 14188篇 |
2017年 | 10838篇 |
2016年 | 11804篇 |
2015年 | 13253篇 |
2014年 | 18249篇 |
2013年 | 27903篇 |
2012年 | 38384篇 |
2011年 | 40419篇 |
2010年 | 24008篇 |
2009年 | 22842篇 |
2008年 | 38682篇 |
2007年 | 41483篇 |
2006年 | 41542篇 |
2005年 | 40493篇 |
2004年 | 39459篇 |
2003年 | 38235篇 |
2002年 | 37472篇 |
2001年 | 64564篇 |
2000年 | 67012篇 |
1999年 | 56571篇 |
1998年 | 14556篇 |
1997年 | 13126篇 |
1996年 | 13544篇 |
1995年 | 13536篇 |
1994年 | 12859篇 |
1993年 | 11826篇 |
1992年 | 44730篇 |
1991年 | 43653篇 |
1990年 | 42352篇 |
1989年 | 40269篇 |
1988年 | 37015篇 |
1987年 | 36375篇 |
1986年 | 33731篇 |
1985年 | 32409篇 |
1984年 | 24242篇 |
1983年 | 20319篇 |
1982年 | 11776篇 |
1981年 | 10728篇 |
1979年 | 21403篇 |
1978年 | 14853篇 |
1977年 | 12563篇 |
1976年 | 11716篇 |
1975年 | 12660篇 |
1974年 | 14718篇 |
1973年 | 14165篇 |
1972年 | 12986篇 |
1971年 | 11752篇 |
1970年 | 11072篇 |
1969年 | 10055篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
2.
Rozhkov V. P. Trifonov M. I. Soroko S. I. 《Neuroscience and behavioral physiology》2022,52(3):383-394
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia... 相似文献
3.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
4.
5.
6.
7.
8.
9.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
10.
Medicine, Health Care and Philosophy - In this paper, I will provide a phenomenological analysis of somatic obsessions at times present in obsessive–compulsive disorder. I will compare two... 相似文献